Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital Zhejiang ,University School of Medicine, Hangzhou, Zhejiang, China.
Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou, China.
Cancer Biol Ther. 2020 Dec 1;21(12):1105-1108. doi: 10.1080/15384047.2020.1836549. Epub 2020 Nov 5.
Here we present a case of metastatic small bowel adenocarcinoma, which progressed after sequential treatment with XELOX (capecitabine and oxaliplatin), FOLFIRI (fluorouracil, leucovorin, and irinotecan), cetuximab, HER-2 targeted therapy and apatinib and was then effectively controlled by fruquintinib. Genetic testing showed wild-type KRAS/NRAS/BRAF, HER-2 amplification, and microsatellite stable. Then the patient started to receive fruquintinib and has already achieved a 6-month progression-free survival. Till Jun 2019, the treatment with fruquintinib is still ongoing and no severe adverse effect has been seen so far. Although fruquintinib is not, at present, a standard therapeutic strategy recommended by the treatment guideline for advanced small bowel adenocarcinoma, the significant curative effect has been seen in our clinical practice.
在这里我们报告一例转移性小肠腺癌病例，该患者在序贯接受 XELOX（卡培他滨和奥沙利铂）、FOLFIRI（氟尿嘧啶、亚叶酸钙和伊立替康）、西妥昔单抗、HER2 靶向治疗和阿帕替尼治疗后进展，随后使用呋喹替尼治疗得到有效控制。基因检测显示 KRAS/NRAS/BRAF 野生型、HER2 扩增和微卫星稳定。随后患者开始接受呋喹替尼治疗，目前已实现 6 个月的无进展生存期。截至 2019 年 6 月，患者仍在接受呋喹替尼治疗，目前尚未观察到严重的不良反应。虽然呋喹替尼目前不是晚期小肠腺癌治疗指南推荐的标准治疗策略，但在我们的临床实践中已观察到显著的疗效。
